Probiotic LR607 for newly diagnosed lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a probiotic supplement (LR607) can help patients with newly diagnosed non-small cell lung cancer—a common type of lung cancer. Probiotics are beneficial bacteria that may help your immune system fight cancer alongside standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed non-small cell lung cancer confirmed by biopsy
- Good overall health and ability to care for yourself (ECOG score 0–1)
- Age 18 or older
- At least one measurable tumor visible on imaging scans
- Healthy organ function (liver, kidney, heart, bone marrow) to tolerate treatment
- No active autoimmune diseases, recent immune-suppressing medications, or lung scarring (interstitial lung disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with non-small cell lung cancer. Researchers are also studying how the bacteria in your gut (microbiome) affect how well the treatment works. This approach may shrink the tumor and make it easier to remove surgically.
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests if taking a probiotic supplement along with your standard lung cancer treatment can help you live longer and respond better to therapy. It is for people with advanced non-small cell lung cancer who have not tried immunotherapy before.
Hear when a new NSCLC Diagnosed by Histology or Cytology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.